These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3019897)

  • 21. Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones.
    Fu KP; Grace ME; McCloud SJ; Gregory FJ; Hung PP
    Chemotherapy; 1986; 32(6):494-8. PubMed ID: 3026740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanism of action of quinolones].
    Smith JT
    Infection; 1986; 14 Suppl 1():S3-15. PubMed ID: 2420724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
    Hilliard JJ; Krause HM; Bernstein JI; Fernandez JA; Nguyen V; Ohemeng KA; Barrett JF
    Adv Exp Med Biol; 1995; 390():59-69. PubMed ID: 8718602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mode of action of 4-quinolones and possible mechanisms of resistance.
    Smith JT
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():21-9. PubMed ID: 3542946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
    Fabbri S; Broggini M; Pagella P; D'Incalci M
    J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
    [No Abstract]   [Full Text] [Related]  

  • 27. Electrochemical characteristics of five quinolone drugs and their effect on DNA damage and repair in Escherichia coli.
    Thomas A; Tocher J; Edwards DI
    J Antimicrob Chemother; 1990 May; 25(5):733-44. PubMed ID: 2165050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R; Garrigues TM; Cantón E
    Rev Esp Quimioter; 2002 Mar; 15(1):25-31. PubMed ID: 12582434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis.
    Chatterji M; Unniraman S; Mahadevan S; Nagaraja V
    J Antimicrob Chemother; 2001 Oct; 48(4):479-85. PubMed ID: 11581225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
    Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
    J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.
    Collin F; Karkare S; Maxwell A
    Appl Microbiol Biotechnol; 2011 Nov; 92(3):479-97. PubMed ID: 21904817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolone uptake by bacteria and bacterial killing.
    Diver JM
    Rev Infect Dis; 1989; 11 Suppl 5():S941-6. PubMed ID: 2549609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usual and unusual antibacterial effects of quinolones.
    Furet YX; Pechère JC
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():7-15. PubMed ID: 2175306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
    McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
    J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs.
    Ito T; Kojima K; Koizumi K; Nagano H; Nishino T
    Biol Pharm Bull; 1994 Jul; 17(7):927-30. PubMed ID: 8000379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of topoisomerase function in bacterial replication fork movement: use of DNA microarrays.
    Khodursky AB; Peter BJ; Schmid MB; DeRisi J; Botstein D; Brown PO; Cozzarelli NR
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9419-24. PubMed ID: 10944214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
    Onodera Y; Uchida Y; Tanaka M; Sato K
    J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.